SecBot SecBot
8-K ·Filed Apr 15, 2026

HRGN

Harvard Apparatus Regenerative Technology, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed6mo ago SEC0001437749-26-012380
8-K material event: Items 1.02
Actionable Insight • Neutral

Investors should note this is new debt financing, not a termination. The CEO lending money suggests confidence but also highlights cash constraints. Monitor for future capital raises that could trigger conversion and dilution.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
HRGN ▼ -33.21% at T+60d
NEUTRAL call -33.21% · α vs SPY -40.25% · entry $1.57 → $1.05
Entry = T+0 close
Apr 15, 2026
via day close
T+1d
0.00%
call 0.00% · α -1.21%
$1.57
settled 6mo ago
T+5d
-2.04%
call -2.04% · α -3.02%
$1.54
settled 6mo ago
T+20d
-4.58%
call -4.58% · α -10.40%
$1.50
settled 6mo ago
T+60d
-33.21%
call -33.21% · α -40.25%
$1.05
settled 4mo ago

Price Chart

Loading chart...

Executive Summary

Harvard Apparatus Regenerative Technology, Inc. (HRGN) did not terminate a material agreement as the 8-K filing suggests; instead, it entered into a $300,000 bridge loan with its CEO, Junli He. The filing incorrectly labels this new financing as a termination under Item 1.02, creating confusion. The loan bears 8% interest and matures upon the earlier of a $5M capital raise or April 13, 2027, with optional conversion to equity.

Key Facts

  • Filing incorrectly reports 'Termination of a Material Definitive Agreement' under Item 1.02
  • Actual event: Company entered into a $300,000 bridge loan with CEO Junli He
  • Loan carries 8% annual interest and matures on earlier of $5M capital raise or April 13, 2027
  • Note includes optional conversion feature at lender's discretion
  • Filing contains material mislabeling of transaction type

Financial Impact

Company received $300,000 in new financing from its CEO at 8% interest, with potential future dilution if converted to equity

debtcashdilution

Risk Factors

  • CEO lending to company may indicate liquidity concerns
  • Potential dilution if the note converts in a future financing
  • Filing error raises questions about internal controls

Market Snapshot

Exchange
OTC
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001437749-26-012380
Exhibit: ex_946099.htm0001437749-26-012380
Document: 0001437749-26-012380-index-headers.html0001437749-26-012380
Document: 0001437749-26-012380-index.html0001437749-26-012380
Document: 0001437749-26-012380.txt0001437749-26-012380
4 reports for HRGN
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for HRGN — sortable, filterable
TypeNow
Sep 14, 2026
6w ago
8-K
BEARISH ★ 5/10
$1.96 $2.12▼ −8.16%▼ −5.65%$1.96 (−0.10%)
Aug 3, 2026
12w ago
8-K
BEARISH ★ 5/10
$1.00 $1.58▼ −58.00%▼ −56.76%$1.96 (−96.20%)
Apr 28, 2026
25w ago
8-K
NEUTRAL ★ 4/10
$1.57 $1.30▼ −17.04%▼ −23.09%$1.96 (+25.21%)
Apr 15, 2026
27w ago
8-K
NEUTRAL ★ 5/10
$1.57 $1.50▼ −4.58%▼ −10.40%$1.96 (+24.81%)
Showing 4 of 4

US Market Status

Market Closed — Opens Tue (16h 37m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 15, 2026